'Some of the most effective therapies we have,' says Loretta Nastoupil
— "Some of the most effective therapies we have," says Loretta Nastoupil
by Gregory Laub, Senior Director, Video, MedPage Today
June 22, 2026
• 3 min read
At the American Society of Clinical Oncology (ASCO) meeting, new subgroup and real-world analyses added to the growing evidence for bispecific antibodies in relapsed follicular lymphoma, while also highlighting practical questions around their use outside academic centers.
FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma
Nuove cure a disposizione per i tumori del sistema linfatico, leucemia linfatica cronica e linfoma mantellare
High response rates and manageable safety were seen across high-risk patient groups
In this video, Paolo Strati, MD, discusses the potential of bispecific antibody and antibody-drug conjugate combination therapy…
VIDEO: Immunotherapies offer new opportunities in relapsed, refractory myeloma
Two late-stage trials presented at ASCO show major advances for patients with relapsed multiple myeloma, including an oral drug…
CHICAGO — The bispecific antibody linvoseltamab exhibited rapid clinical activity among patients with relapsed or refractory…
Seeking a share of the first-line diffuse large B-cell lymphoma (DLBCL) market, Incyte believes Monjuvi’s positive phase 3…
